Drug intelligence / Profile preview

MD20

Development stage: Preclinical
Lead developer: Radella Pharmaceuticals
Modality: Small Molecules
Administration: Topical

Overview

MD20 is a newly synthesized 1,4-Dihydropyridine (DHP) derivative. It functions as a novel calcium channel blocker, selectively targeting the T-type calcium channel (Cav3.2) over the L-type calcium channel (Cav1.2). It is being investigated for potential topical use in the treatment of neuropathic pain. Studies have also focused on its amorphous form, thermal properties, molecular dynamics, and physical stability, showing increased stability when formulated with Pluronic surfactants and α-tocopherol.

Targets

CaV3 (Caveolin-3)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)

Beyond the preview

Go deeper on MD20.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MD20.

Explore the full profile